Elacestrant + Onapristone
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Dec 2, 2022 → Jun 23, 2023
NCT ID
NCT05618613About Elacestrant + Onapristone
Elacestrant + Onapristone is a phase 1/2 stage product being developed by Context Therapeutics for Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05618613. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06938711 | Phase 1/2 | Withdrawn |
| NCT05618613 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Breast Cancer